These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1614055)

  • 21. Deferoxamine and aluminum clearance in pediatric hemodialysis patients.
    Ogborn MR; Dorcas VC; Crocker JF
    Pediatr Nephrol; 1991 Jan; 5(1):62-4. PubMed ID: 2025542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 23. Chromatographic studies of aluminum-desferrioxamine complex in uremic patients.
    Canavese C; Pacitti A; Salomone M; Pramotton C; Segoloni G; Bedino S; Testore G; Lamon S; Vercellone A
    ASAIO Trans; 1986; 32(1):367-9. PubMed ID: 3778736
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined high-efficiency hemodialysis and charcoal hemoperfusion in severe N-acetylprocainamide intoxication.
    Kar PM; Kellner K; Ing TS; Leehey DJ
    Am J Kidney Dis; 1992 Oct; 20(4):403-6. PubMed ID: 1384320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of combined hemodialysis/hemoperfusion in chronic uremia.
    Stefoni S; Feliciangeli G; Colì L; Prandini R; Bonomini V
    Contrib Nephrol; 1982; 29():123-32. PubMed ID: 6804167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a single session in-series hemoperfusion and hemodialysis in the management of carprofen overdose in two dogs.
    Fick ME; Messenger KM; Vigani A
    J Vet Emerg Crit Care (San Antonio); 2020 Mar; 30(2):226-231. PubMed ID: 32128985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
    Li J; Li D; Xu Y; Wang A; Xu C; Yu C
    Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Removal of chelated aluminium during haemodialysis using polysulphone high-flux dialysers.
    Aarseth HP; Ganss R
    Nephrol Dial Transplant; 1990; 5(11):942-4. PubMed ID: 2127830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion.
    Ludwig SM; McKenzie J; Faiman C
    Am J Kidney Dis; 1987 Dec; 10(6):457-60. PubMed ID: 3687936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperoxalemia in renal failure and the role of hemoperfusion and hemodialysis in primary oxalosis.
    Ahmad S; Hatch M
    Nephron; 1985; 41(3):235-40. PubMed ID: 4058624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
    Anthone S; Ambrus CM; Kohli R; Min I; Anthone R; Stadler A; Stadler I; Vladutiu A
    J Am Soc Nephrol; 1995 Oct; 6(4):1271-7. PubMed ID: 8589296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Artificial cells in medical applications with emphasis on hemoperfusion in aluminium removal and cross-over control clinical trial of reduced time hemoperfusion-hemodialysis.
    Chang TM; Barre P; Lister C; Kuruvilla S
    Contrib Nephrol; 1989; 70():237-49. PubMed ID: 2670432
    [No Abstract]   [Full Text] [Related]  

  • 34. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical aspects and applications of hemofiltration.
    Weiss LG
    Scand J Urol Nephrol Suppl; 1989; 118():1-64. PubMed ID: 2785286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K; Walasek L; Kidawa Z; Lutz W
    Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Routine clinical applications of hemodialysis-hemoperfusion in chronic renal failure: case reports.
    Barré PE; Gonda A; Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):305-8. PubMed ID: 3023242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion.
    Franssen EJ; van Essen GG; Portman AT; de Jong J; Go G; Stegeman CA; Uges DR
    Ther Drug Monit; 1999 Jun; 21(3):289-92. PubMed ID: 10365638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbamazepine clearance in hemodialysis and hemoperfusion.
    Kandrotas RJ; Oles KS; Gal P; Love JM
    DICP; 1989 Feb; 23(2):137-40. PubMed ID: 2728503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential and simultaneous "in series" hemodialysis and hemoperfusion in the management of theophylline intoxication.
    Hootkins R; Lerman MJ; Thompson JR
    J Am Soc Nephrol; 1990 Dec; 1(6):923-6. PubMed ID: 2103852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.